



Virginia Department of Health TB Control Program
TB Risk Assessment Form (TB 512)

Patient name (L,F,M): \_\_\_\_\_ DOB: \_\_\_\_\_ Race: \_\_\_\_\_ Sex: \_\_\_\_\_
Address: \_\_\_\_\_ Social Security Number: \_\_\_\_\_
City, State, ZIP: \_\_\_\_\_ Home/Work #: \_\_\_\_\_
Cell #: \_\_\_\_\_ Language: \_\_\_\_\_ Patient Pregnant: \_\_\_No \_\_\_Yes; If Yes, LMP: \_\_\_\_\_
Country of Origin: \_\_\_\_\_ Year arrived in US: \_\_\_\_\_ Interpreter needed: \_\_\_No \_\_\_Yes Last Live Vaccine: \_\_\_\_\_

I. Screen for TB Symptoms (Check all that apply)

- None (Skip to Section II, "Screen for Infection Risk")
Cough for >= 3 weeks -> Productive: \_\_\_YES \_\_\_NO
Hemoptysis
Fever, unexplained
Unexplained weight loss
Poor appetite
Night sweats
Fatigue
Evaluate these symptoms in context

Pediatric Patients (<= 6 years of age):
Wheezing
Failure to thrive
Decreased activity, playfulness and/or energy
Lymph node swelling
Personality changes

History of BCG / TB Skin Test / TB Treatment:

History of prior BCG: \_\_\_NO \_\_\_YES -> Year: \_\_\_\_\_
History of prior (+) TST: \_\_\_NO \_\_\_YES
Date of (+) TST \_\_\_\_\_ Reading: \_\_\_\_\_mm
CXR Date: \_\_\_\_\_ CXR result: \_\_\_ABN \_\_\_WNL
Dx: \_\_\_LTBI \_\_\_Disease
Tx Start: \_\_\_\_\_ Tx End: \_\_\_\_\_
Rx: \_\_\_\_\_
Completed: \_\_\_NO \_\_\_YES
Location of Tx: \_\_\_\_\_

III. Finding(s) (Check all that apply)

- Previous Treatment for LTBI and/or TB disease
No risk factors for TB infection
Risk(s) for infection and/or progression to disease
Possible TB suspect
previous positive TST, no prior treatment

IV. Action(s) (Check all that apply)

- Issued screening letter Issued sputum containers
Referred for CXR Referred for medical Evaluation
Administered the Mantoux TB Skin Test
Draw interferon-gamma release assay
Other: \_\_\_\_\_

#1 TST Lot# \_\_\_\_\_ or IGRA (Check One)
Date Given or Drawn \_\_\_\_\_ Time \_\_\_\_\_ Site \_\_\_\_\_
Signature \_\_\_\_\_ POS# \_\_\_\_\_
TST READING/ IGRA Results Date Read \_\_\_\_\_
Time \_\_\_\_\_ Signature \_\_\_\_\_ POS# \_\_\_\_\_
Induration \_\_\_\_\_mm \_\_\_Pos \_\_\_Neg (TST or IGRA)
Borderline/Indeterminate - IGRA ONLY

#2 TST Lot# \_\_\_\_\_ or IGRA (Check One)
Date Given or Drawn \_\_\_\_\_ Time \_\_\_\_\_ Site \_\_\_\_\_
Signature \_\_\_\_\_ POS# \_\_\_\_\_
TST READING/ IGRA Results Date Read \_\_\_\_\_
Time \_\_\_\_\_ Signature \_\_\_\_\_ POS# \_\_\_\_\_
Induration \_\_\_\_\_mm \_\_\_Pos \_\_\_Neg (TST or IGRA)
Borderline/Indeterminate - IGRA ONLY

Screener's signature: \_\_\_\_\_
Screener's name(print): \_\_\_\_\_
Date: \_\_\_\_\_ Phone #: \_\_\_\_\_

II. Screen for TB Infection Risk (Check all that apply)

Individuals with an increased risk for acquiring latent TB infection (LTBI) or for progression to active disease once infected should have a TST. Screening for persons with a history of LTBI should be individualized.

A. Assess Risk for Acquiring LTBI The Patient...

- is a current high risk contact of a person known or suspected to have TB disease: Name of Source case: \_\_\_\_\_
lived in or visited another country where TB is common for 3 months or more, regardless of length of time in the U.S.
is a resident or an employee of a high TB risk congregate setting
is a healthcare worker who serves high-risk clients
is medically underserved
has been homeless within the past two years
is an infant, a child or an adolescent exposed to an adult(s) in high-risk categories
injects illicit drugs or uses crack cocaine
is a member of a group identified by the health department to be at an increased risk for TB infection
needs baseline/annual testing approved by the health department

B. Assess Risk for Developing TB Disease if Infected The Patient...

- is HIV positive
has risk for HIV infection, but HIV status is unknown
was recently infected with Mycobacterium tuberculosis
has certain clinical conditions, placing them at higher risk for TB disease:
injects illicit drugs (determine HIV status): \_\_\_\_\_
has a history of inadequately treated TB
is >10% below ideal body weight
is on immunosuppressive therapy - includes treatment with TNF-α antagonists (Remicaid, Humira, etc.), other biologic response modifiers or prednisone >= 1 mo. >=15 mg/day

I hereby authorize the doctors, nurses, or nurse practitioners of the Virginia Department of Health to administer the Tuberculin SkinTest (PPD) or draw blood for an IGRA test from me or my child named above.

- I agree that the results of this test may be shared with other health care providers.
The Deemed Consent for blood borne diseases has been explained to me and I understand it.
I acknowledge that I have received the Notice of Privacy Practices from the Virginia Department of Health.
I understand that:
this information will be used by health care providers for care and for statistical purposes only.
this information will be kept confidential.
medical records must be kept at a minimum for 10 years after my last visit, 5 years after death; for minor children, 5 years after the age of 18, or 10 years after the last visit, whichever is greater.

X \_\_\_\_\_ Date: \_\_\_\_\_
Client or Parent/Guardian Signature